Real-World data on firmonertinib for lung cancer that spread to the brain
NCT ID NCT07239102
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked back at medical records of 300 people with EGFR-positive non-small cell lung cancer that had spread to the brain or spinal cord. All patients were treated with the drug firmonertinib. Researchers analyzed how long the drug controlled brain tumors and explored why some patients stopped responding. The goal is to better understand real-world effectiveness and resistance patterns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Firmonertinib (oral drug)
- What this could lead to
- If successful, this analysis could help identify which patients benefit most from firmonertinib and how resistance develops, guiding future treatment strategies.
- What could go wrong
- This is a retrospective review of past medical records, not a controlled trial. Results may be influenced by incomplete data or patient selection bias.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Li Xiaoyan
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Spinal fluid injection of Dual-Target antibody and chemotherapy shows promise for deadly cancer complication
- Smartwatch could alert doctors to brain cancer complications before they worsen
- Targeted radiation zaps childhood brain tumors in early trial
- New targeted pill could boost lung cancer surgery success
- Triple therapy targets tough brain metastases in lung cancer